To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? by Marciano, N. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/94747  
 
N. J. Marciano, T. L. Merlin, T. Bessen, J. M. Street 
To what extent are current guidelines for cutaneous melanoma follow up based on scientific 
evidence? 
International Journal of Clinical Practice, 2014; 68(6):761-770 
© 2014 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd. This 
is an open access article under the terms of the Creative Commons Attribution-NonCommercial-
NoDerivs License, which permits use and distribution in any medium, provided the original work is 
properly cited, the use is non-commercial and no modifications or adaptations are made. 




























To what extent are current guidelines for cutaneous
melanoma follow up based on scientific evidence?
N. J. Marciano,1 T. L. Merlin,1,2 T. Bessen,1 J. M. Street1,2
SUMMARY
Background: Clinical practice guidelines should aim to assist clinicians in making
evidence-based choices in the care of their patients. This review attempts to deter-
mine the extent of evidence-based support for clinical practice guideline recom-
mendations concerning cutaneous melanoma follow up and to evaluate the
methodological quality of these guidelines. Methods: Current guidelines providing
graded recommendations regarding patient follow up were identified through a
systematic literature review. The authors reviewed the evidence base used to for-
mulate recommendations in each of the guidelines and appraised the quality of
the guidelines using the AGREE II (Appraisal of Guidelines for Research and Evalu-
ation) instrument. Results: Most guideline recommendations concerning the fre-
quency of routine skin examinations by a clinician and the use of imaging and
diagnostic tests in the follow up of melanoma patients were based on low-level
evidence or consensus expert opinion. Melanoma follow-up guidelines are of vari-
able methodological quality, with some guidelines not recommended by the
appraisers for use in clinical practice. Conclusion: Clinicians should be aware of
how scant the evidence base is for many recommended courses of action. As a
consequence of the paucity of evidence in the field of melanoma follow up, there
is considerable variability in the guidance provided. The variable methodological
quality of guidelines for melanoma follow up could be improved by attention to
the criteria described in AGREE II.
Review criteria
• A search of 11 electronic databases and websites
was conducted to identify potentially relevant
guidelines published in 2006 or later, in addition
to use of a review article by Speijers et al.
• Relevant guidelines were selected based on
PIPOH criteria, which were delineated prior to
collating the literature.
• Authors identified the evidence supporting follow-up
recommendations in each guideline.
• Authors appraised guideline quality using AGREE
II.
Message for the clinic
• Melanoma follow-up recommendations concerning
frequency of physical examinations, duration of
follow-up appointments and use of imaging or
diagnostic tests are based mostly on low-level
evidence or consensus expert opinion. The level of
uncertainty associated with these
recommendations is often not apparent from the
way the guideline is presented for the
development.
• Clinicians should further investigate the metho-
dology and evidence supporting melanoma
follow-up recommendations before applying them
in the clinical setting.
Background
Australia and New Zealand have the highest inci-
dence of melanoma in the world, with an age-stan-
dardised incidence in Australia of 48.8 per 100,000
in 2008, meaning that the average person has a 1 in
18 risk of being diagnosed with the disease before
age 85 (1,2). Data from the 2008 American Joint
Committee on Cancer Melanoma Staging Database
show that 10-year survival rates range from 93% for
stage IA to 39% for stage IIC (3). In Australia, mela-
noma patients had the third highest 5-year survival
rates of all cancers at 92% from 1998 to 2004 (4).
Consequently, in Australia and other developed
nations, there is a growing pool of melanoma survi-
vors who will require follow up for disease recur-
rence. Evidence-based guidance is needed on how
often and what type of follow up is required for
these patients. Patient follow up is characterised by
appointments where physical examinations and/or
diagnostic tests are performed in accordance with a
prescribed schedule. Follow up serves a number of
purposes: to facilitate the early detection of recurrent
tumours and to enable swift action to be taken if a
recurrence is detected (5), to reassure patients, to
provide a vehicle for continuing education regarding
skin self-assessment, for management of treatment-
related side effects and an opportunity to provide
psychosocial support (6).
Guidelines may be described as ‘systematically
developed statements to assist practitioner and
patient decisions about appropriate healthcare for
specific clinical circumstances’ (7). Guideline recom-
mendations may be based on either scientific evi-
dence or the expertise of the guideline developers via
a consensus decision-making process. Central to the
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development of evidence-based guidelines, as
opposed to consensus-based guidelines, is a critique
of the quality and strength of evidence supporting
recommended courses of action and the selection of
the best available evidence through a rigorous sys-
tematic review of the available literature (8).
Guideline recommendations vary between coun-
tries or agencies of origin, and this is often thought
to be because of the need to ‘localise’ the available
international evidence so that it is relevant to clinical
practice within the targeted health system and target
population. However, a recent comparison of seven
guidelines for the management of posttraumatic
stress disorder has noted that differences between
guidelines are often because of insufficient empirical
data to drive the recommendations (9). When
research evidence is limited, transparency and rigour
in guideline development are imperative to assist the
interpretation of guideline recommendations. The
Guidelines International Network (GIN), formed in
Paris in 2002 (10), seeks to improve the quality of
guideline development and reduce inappropriate var-
iation through the establishment and promotion of
high-quality standards of guideline development
(10). In 2003, the AGREE (Appraisal of Guidelines
for Research and Evaluation) collaboration published
well-defined methodological criteria for guideline
development (11) which were updated (AGREE II)
in 2010 (8). Nevertheless, two reviews of clinical
practice guidelines, published in 2007 and 2009, deal-
ing with prevention of cardiovascular disease and
prostate cancer follow up, respectively, found that
guidelines were mostly of poor methodological qual-
ity and lacked transparency (12,13). Given the
increasing need for guidance on the clinical follow
up of melanoma survivors, it would be helpful to
know whether the available ‘evidence-based’ guide-
lines can be trusted. This study aims to determine
whether clinical practice guidelines on the follow up
of patients diagnosed with cutaneous melanoma are
evidence based; evaluate whether the processes used
to develop these guidelines were rigorous and trans-
parent; and ascertain whether practice recommenda-
tions are consistent across the guidelines.
Methods
Selection of cutaneous melanoma follow-up
guidelines
A search of 11 electronic databases and websites was
conducted in February 2013 to identify potentially
relevant guidelines: EMBASE; PubMed (Medline);
Australian Government National Health and Medical
Research Council (NHMRC) Guidelines Portal;
National Guidelines Clearinghouse (NGC); GIN
Library; Ontario Guideline Advisory Committee
(GAC); Canadian Agency for Drugs and Technology
in Health (CADTH); National Health Services
(NHS) Guidelines Finder; Royal College of Physi-
cians (RCP) Guideline Database; National Institute
of Health and Clinical Excellence (NICE); New Zea-
land Guidelines Group (NZGG) and Scottish Inter-
collegiate Guidelines Network (SIGN). In addition, a
recent review article by Speijers et al. (14) citing 19
mostly European melanoma follow-up guidelines (15
of which were published in 2006 or later) was used
to source guidelines that might not have been
indexed in the standard databases.
The database search was not specific for follow up,
instead aiming to retrieve all guidelines specific to
skin cancer, to capture more general guidelines
which include a description of melanoma follow up.
Terms used in the search were melanoma, skin, cuta-
neous, dermal, cancer, neoplasm and tumour. Guide-
lines published, revised or reaffirmed during the
period from 2006 to February 2013 were included.
Only one clinical practice guideline per independent
organisation, i.e. the most recently published full
guideline, was selected.
The study selection process (Figure 1) applied
PIPOH (15) selection criteria. To reduce bias, these
criteria were delineated prior to collating the litera-
ture and included: patient population (people with
suspected or proven diagnosis of cutaneous mela-
noma), intervention (follow up of melanoma
patients), professionals or target audience of the
guideline (general practitioners, oncologists, derma-
tologists, surgeons, physicians or other referred spe-
cialists) and healthcare setting (primary, secondary
or tertiary). In addition, guidelines were excluded if
they: had only recommendations that were developed
solely on the basis of consensus; were summaries of
another guideline; were not in English (or translated
into English); had no explicit grading system for
determining the strength of recommendations; had
no melanoma follow-up recommendations; referred
to another guideline for all melanoma follow-up rec-
ommendations; were not based on a systematic liter-
ature review; were replaced by a more recent version
of the guideline or had expired (past the stated due
date for updating).
Initial guideline eligibility on the basis of the col-
lated guidelines was conservatively determined by
two authors. When consensus could not be reached,
another two reviewers independently assessed the
guideline in question and the majority decision pre-
vailed. Melanoma follow-up recommendations were
extracted from each guideline and compared, and
the evidence cited as supporting each recommenda-
tion was also extracted.
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Evaluation of guidelines
The AGREE II instrument provided a framework to
assess the comparative quality of the different guide-
lines (8). This tool was used by the four authors to
independently assess each guideline. The authors
provided a range of experience in guideline develop-
ment and evaluation, with perspectives including an
experienced guideline developer and methodologist,
a clinician, a public health academic and a research
assistant.
The AGREE II instrument is comprised of 23
items under six domains: scope and purpose, stake-
holder involvement, rigour of development, clarity of
presentation, applicability and editorial independence
(see Table 1 for descriptions of each item). Each
item is given a rating by assessors from 1 to 7, with
1 indicating ‘strongly disagree’ and 7 indicating
‘strongly agree’ (8).
In accordance with AGREE II methodology, mean
domain scores were calculated by summing up all
the scores of the individual items in a domain and
by scaling the total as a percentage of the maximum
possible score for that domain across all the four
reviewers (see Figure 2) (8). The six domain scores
are independent and are not intended to be aggre-
gated into a single overall quality score; rather,
appraisers give a separate overall score of 1–7 and
are asked whether they would recommend the guide-
line for use (8). An average overall score for each
guideline was calculated using the overall scores of
the four reviewers.
Results
The guideline selection process is represented dia-
grammatically in Figure 1. A total of 3981 records
were retrieved in the initial literature search,
although the vast majority of these were excluded
after screening of title and abstract because they were
unrelated to melanoma, skin cancer or cancer screen-
ing/surveillance or not clinical practice guidelines.
Subsequently, the remaining 53 guidelines were eval-
uated, and following the application of PIPOH crite-
ria and use of the consensus process, 44 guidelines
were excluded. Reasons for exclusion included guide-
lines not in English (n = 12); guidelines with no rec-
ommendations (n = 11); guidelines were not the
most recent publication (n = 9); non-original guide-
lines (n = 6); not based on systematic review
(n = 3); patient-oriented guidelines (n = 2) and no
recommendation grading system (n = 1).
The included guidelines (n = 9) are listed in
Table 2. Included guidelines were published by or-
ganisations from the United States (n = 4); Australia
and New Zealand (n = 1); Scotland (n = 1); the
United Kingdom (n = 1); Switzerland (n = 1) and
Europe (n = 1).
Melanoma follow-up recommendations
Recommendations for the follow up of cutaneous
melanoma from each guideline were compiled for
comparing the evidence base used by each guideline
and to determine the consistency of the guidance
Studies identified in electronic literature search using EMBASE; PubMed (Medline); 
NHMRC; NGC; GIN; GAC; CADTH; NHS; RCP; NICE; NZGG; SIGN; and Speijers et al. (14)
review article (n = 3981)
Records excluded after reading title and 
abstracts (n = 3928)
Irrelevant topic or not clinical practice 
guidelines 
Potentially relevant guidelines retrieved for 
further evaluation (n = 53) Guidelines excluded (n = 44)
Not English (n = 12) 
No recommendations (n = 11) 
Not most recent publication (n = 9) 
Non-original guidelines (n = 6) 
Not based on systematic review (n = 3) 
Patient-oriented guidelines (n = 2) 
No recommendation grading system (n = 1) 
Guidelines included in analysis (n = 9) 
Figure 1 Diagram of guideline selection
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that was formulated. All guidelines dealt with the
self-examination and education aspect of follow up
and all guidelines made at least one recommendation
regarding frequency and duration of follow up. All
guidelines except COG (16) made recommendations
concerning the imaging/diagnostic test components
of melanoma follow up.
Self-examination and education
All guidelines agreed that patients should be taught
skin self-examination as this was the method by
which recurrences were most commonly detected
(16–24). In addition, educating family members
about self-examination was recommended by ASPS
(18). Education about sun-smart behaviour at rou-
tine visits was recommended by CCA (19), ESMO
(22), SAKK (23) and NCCN (21). The recommenda-
tion, found in all the guidelines, that patients should
be educated in self-examination to support early
detection, is based primarily on consensus and/or
clinical experience. To support this recommendation,
each of the guidelines used evidence which was dif-
ferent from that used in any other guideline. In addi-
tion, the evidence content varied between guidelines:
CCA guidelines relied on evidence showing that most
patients detect their own recurrence (19); ASPS
guidelines relied on the finding that second primaries
are thinner than first primaries or are thinner in
ASPS guideline: Scope and Purpose Domain 
Scores Item 1 Item 2 Item 3 
Appraiser #1 5 2 4 
Appraiser #2 6 1 3 
Appraiser #3 6 2 5 
Appraiser #4 6 2 4
Total score: 23 7 16 46 
Obtained score = sum of all scores of all appraisers within the domain = 46 
Maximum possible score = 7 (strongly agree) × 3 (# of items in domain) × 4 (# of appraisers) = 84 
Minimum possible score = 1 (strongly agree) × 3 (# of items in domain) × 4 (# of appraisers) = 12 
Figure 2 Example calculation of an AGREE II domain score
Table 1 AGREE II instrument domains and items
Domain Item
Scope and purpose 1 The overall objective(s) of the guideline is (are) specifically described
2 The health question(s) covered by the guideline is (are) specifically described
3 The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described
Stakeholder involvement 4 The guideline development group includes individuals from all relevant professional groups
5 The views and preferences of the target population (patients, public, etc.) have been sought
6 The target users of the guideline are clearly defined
Rigour of development 7 Systematic methods were used to search for evidence
8 The criteria for selecting the evidence are clearly described
9 The strengths and limitations of the body of evidence are clearly described
10 The methods for formulating the recommendations are clearly described
11 The health benefits, side effects and risks have been considered in formulating the recommendations
12 There is an explicit link between the recommendations and the supporting evidence
13 The guideline has been externally reviewed by experts prior to its publication
14 A procedure for updating the guideline is provided
Clarity of presentation 15 The recommendations are specific and unambiguous
16 The different options for management of the condition or health issue are clearly presented
17 Key recommendations are easily identifiable
Applicability 18 The guideline describes facilitators and barriers to its application
19 The guideline provides advice and/or tools on how the recommendations can be put into practice
20 The potential resource implications of applying the recommendations have been considered
21 The guideline presents monitoring and/or auditing criteria
Editorial independence 22 The views of the funding body have not influenced the content of the guideline
23 Competing interests of guideline development group members have been recorded and addressed
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those patients who are educated (18); American
Academy of Dermatology (AAD) relied on both
(20). SIGN guidelines relied on evidence showing
that information provision can reduce distress
and possibly thereby improve survival (17).
COG, ESMO, SAKK, NCCN and BAD provided
no evidence to support this recommendation
(16,21–24).
Follow-up frequency and duration
Recommendations for the frequency and duration of
follow up are summarised in Table 3. CCA was the
only guideline to mention that the frequency of fol-
low up may be affected if a patient is enrolled in a
clinical trial (19). Although all guidelines recom-
mended follow up for medium-to–high-risk mela-
noma patients, they offered little or no evidence to
support its use. CCA, AAD, ASPS, BAD and SAKK
acknowledged that most melanoma recurrences are
detected by the patient (18–20,23,24), but BAD also
suggested that physician detection of melanoma is
important (24). A prospective study by Garbe et al.
(25) that claims to demonstrate the efficacy of routine
follow up was cited by CCA, SIGN and the AAD
guidelines (17,19,20), although the study does not
exclude the possibility of lead time bias. The BAD
(24) guidelines referenced a consensus-based guide-
line also written by Garbe et al. (26). The SAKK (23)
guidelines share some authors with the ESMO (22)
guidelines and cite another German guideline written
by Garbe et al. (27). The SAKK and ESMO guidelines
also cite each other (22,23). The CCA, ASPS, SIGN
and AAD (17–20) guidelines cite a range of studies
that show there is no survival advantage for patients
receiving intense routine surveillance: Baughan et al.
(28) cited by CCA; Hofmann et al. (29) cited by
CCA, ASPS and AAD; Shumate et al. (30) cited by
SIGN; Mooney et al. (31) cited by SIGN and CCA;
Tsao et al. (32) cited by ASPS. The NCCN guidelines
only cite studies published in the early 1990s relating
to psychosocial support, detection of a subsequent
secondary primary melanoma and screening for sec-
ond non-melanoma primary malignancies as reasons
in favour of a structured follow-up programme (21).
ESMO’s only recommendation relating to frequency
of follow up states that there is no consensus on the
optimal schedule (22).
Diagnostic/imaging tests
Recommendations for the use of diagnostic/imaging
tests as part of follow-up care are summarised in
Table 4. All the recommendations for the use of tests
in follow up are based on low-level evidence, primar-
ily case series, diagnostic accuracy studies or prog-
nostic cohort studies. With one exception, the
studies used to support the SIGN (17) guideline rec-
Table 2 Guidelines included in analysis of follow-up recommendations
Guideline title Organisation Scope Year, Countries
Clinical Practice Guidelines for the Management
of Melanoma in Australia and New Zealand
Cancer Council Australia; Australian
Cancer Network; Ministry of Health,
New Zealand (CCA)
Cutaneous melanoma 2008, Australia and New Zealand




Cutaneous melanoma 2003 (updated 2004, reaffirmed 2007,
2011), Scotland
Revised UK Guidelines for the Management of
Cutaneous Melanoma 2010
British Association of Dermatologists
(BAD)
Cutaneous melanoma 2010, UK
Evidence-based Clinical Practice Guideline:
Treatment of Cutaneous Melanoma
American Society of Plastic Surgeons
(ASPS)
Cutaneous melanoma 2007, USA
Long-term Follow-up Guidelines for Survivors of
Childhood, Adolescent, and Young Adult
Cancers
Children’s Oncology Group (COG) General health and common
adult onset cancers
2006 (updated 2008), USA
Guidelines of Care for the Management of
Primary Cutaneous Melanoma
American Academy of Dermatology
(AAD)
Cutaneous melanoma 2011, USA
Cutaneous Melanoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow
up
European Society for Medical Oncology
(ESMO)
Cutaneous melanoma 2012, Europe
Updated Swiss Guidelines for the Treatment
and Follow up of Cutaneous Melanoma
Project Group Melanoma of the Swiss
Group for Clinical Cancer Research
(SAKK)
Cutaneous melanoma 2011, Switzerland
Melanoma National Comprehensive Cancer
Network (NCCN)
Cutaneous melanoma 2012, USA
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ommendations were published before 2000. Similarly,
the studies used by CCA (19) to reject the use of
tests except for ultrasound are also pre-2000. NCCN
(21) cites studies that report low yield, significant
rates of false positives and risks of radiation exposure
from medical imaging, but still recommend that
imaging should be considered in some cases. CCA
and SAKK recommend the use of ultrasound in
high-risk patients (19,23), whereas AAD and SIGN –
using similar evidence – do not (17,20). ESMO
recommends a serum S-100 blood test instead of lac-
tate dehydrogenase because it has higher specificity
for disease progression, i.e. ‘if any blood test is done
at all’ (22), and in another recommendation states
that there is no consensus on the utility of imaging
and blood tests (22).
AGREE II domains
The AGREE II instrument domain scores for each
guideline, averaged across the four reviewers, are
given in Table 5. The two domains of greatest inter-
est for the authors, given the purpose of this study,
were ‘rigour of development’ and ‘overall guideline
quality’.
Rigour of development
This domain encompasses 8 of the 23 items in the
AGREE II instrument (8). Methods used to search
for evidence were adequate in most guidelines, but
only CCA (19) searched a wide variety of databases,
listed time periods searched, search terms used and
included an appendix detailing the whole search
strategy. Description of the criteria used for selecting
evidence was relatively poor for most guidelines, with
some guidelines only mentioning language type and
most not mentioning eligibility criteria such as study
design or health outcomes of interest. A formal grad-
ing system and appraisal of literature were necessary
for the guideline to receive a high AGREE score on
this domain because the system enables a description
of the strengths and limitations of the guidelines’
body of evidence. In addition, it was essential that
there was some consideration of consistency of
results across studies and their applicability in prac-
tice. Expert consensus was often stated as the method
used for formulating recommendations. Guidelines
that described their methods for obtaining consensus
[COG (16)] scored more highly than those merely
stating that a consensus process had been employed
Table 3 Follow-up frequency and duration
Guideline Recommendations
CCA Stage 0: No recommendation
Stage I: 2/year (first 5 years), then 1/year
Stage II: 3–4/year (first 5 years), then 1/year
Stage III: 3–4/year (first 5 years), then 1/year
Stage IV: No recommendation
SIGN Stage 0: No follow up required
Stages I–III: ‘longer in stage III than in stages I and II’
Stages III–IV: ‘lifelong follow up may be necessary for stages III and IV’
BAD Stage 0: No follow up required
Stage IA: 2–4/year (first year), then discharge
Stages IB–IIIA: 4/year (first 3 years), then 2/year (next 5 years), then discharge
Stages IIIB-C and resected IV: further follow up of 1/year (for 10 years)
ASPS No stage specified: 4/year (first year), then 2/year (for 5 years), then at least 1/year (more frequently for high-risk patients)
COG No stage specified: Annual follow up with monthly self-exam
AAD No stage specified: Annual follow up
ESMO There is no consensus on the optimal follow-up schedule and frequency of follow up
SAKK Stage 0: No recommendation
Stage I (≤T1N0): every 6 months (years 1–3), every 12 months (years 4–10)
Stages I (T2N0), IIA, IIB: every 6 months (years 1–3), every 12 months (years 4–5), every 6–12 months (years 6–10)
Stages IIC, III: every 3 months (years 1–5), every 6 months (years 6–10)
Stage IV: ‘individual’
NCCN Stage 0: At least annual skin exam for life; monthly self skin exam
Stages IA–IIA: every 3–12 months (first 5 years), then annually as clinically indicated, monthly self skin exam
Stages IIB–IV: every 3–12 months (first 5 years), then every 3–12 months (for 3 years), then annually as clinically
indicated; monthly skin self-examination
Text in quotations is taken directly from the guidelines.
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[ASPS (18)]. ESMO, SAKK and NCCN guidelines
did not state any method for formulating recommen-
dations (21–23). Health benefits, side effects and
risks were adequately outlined in most guidelines,
nevertheless appraisers thought that the explicit dis-
cussion of complications and side effects was lacking
in AAD and ASPS (18,20). The way that guidelines
linked evidence to recommendations varied greatly.
The most transparent format was that of the
NHMRC-endorsed CCA (19) guidelines, which com-
prised an evidence summary box with references and
grading of the level of evidence for each individual
recommendation. Most guidelines were able to dem-
onstrate congruency between the evidence and the
recommendations. The ESMO guidelines provided
in-text referencing, but lacked a link between recom-
mendations and evidence (22). Guidelines with no
expert external review at all were scored poorly,
whereas those with detailed explanations of the pur-
pose, method and outcomes received higher scores.
Guidelines that included information about how out-
comes of the external review were applied to the
Table 4 Diagnostic/imaging tests








CCA Stage IV No No No No No
SIGN No No No No No No
BAD No Consider in
stages IIIB–IV
No No No Stage IV






Stages II and III
COG













‘No’ indicates that the test was recommended against. Blank areas indicate that no recommendation was made.


















this guideline for use?
CCA 61 83 95 85 26 44 5.8 3 Yes
1 Yes, with modifications
SIGN 61 86 60 86 61 10 5.0 4 Yes, with modifications
BAD 33 54 50 94 42 46 5.0 2 Yes
2 Yes, with modifications
ASPS 47 26 44 75 3.1 2.1 4.0 3 Yes, with modifications
1 No
COG 71 93 79 82 42 79 6.0 4 Yes
AAD 60 31 29 74 3.1 83 2.8 4 No
ESMO 15 21 20 65 4.2 27 2.5 4 No
SAKK 46 25 21 39 8.3 56 3.0 4 No
NCCN 28 44 29 60 14 35 3.5 4 Yes, with modifications
Mean 46.9 51.4 47.4 73.3 22.6 42.5
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guideline development process generally scored
higher than those that did not. Better guidelines usu-
ally included a methodology or timeline for updating
the guideline rather than a simple statement that the
guideline would be updated.
Overall guideline quality
Ultimately, the COG (16) guidelines were rated as
having the best quality, with highest scores in two of
six domains. The CCA (19) guidelines were also
unanimously recommended for use; however, one
reviewer noted that there were some gaps in the
guideline, such as the lack of auditing criteria. Modi-
fications suggested for the SIGN (17) guidelines
included better discussion of article selection, applica-
bility and more information regarding editorial inde-
pendence. Two appraisers would modify the BAD
(24) guidelines to include detailed criteria for select-
ing evidence and consideration of potential resource
implications of applying the recommendations. The
ASPS (18) guideline was recommended with modifi-
cations by three appraisers and not recommended by
one on the grounds that the guideline was generally
vague and tended to describe current practice rather
than provide evidence-based recommendations. The
other three reviewers noted that although there were
deficiencies in some applicability and editorial inde-
pendence items, methodological rigour and clarity of
presentation were good. The AAD (20) guidelines
received higher domain scores than ASPS (18) in
three of the six domains, and equal scores in another
domain and slightly less than ASPS in another
domain. Nevertheless, ASPS (18) received more
favourable recommendations than AAD (20), with
the appraisers noting that AAD guidelines – accord-
ing to AGREE criteria – lacked transparency, rigour
and multidisciplinary engagement. NCCN (21) guide-
lines did not report on some of the methodological
features included in other guidelines, but were clearly
presented and slightly more rigorous than SAKK
guidelines (23). ESMO (22) guidelines were brief and
did not report on most methodological features usu-
ally expected to be included in an evidence-based
clinical practice guideline.
Discussion
Summary of main finding
The paucity of evidence in the field of melanoma fol-
low up has been borne out by the comparison of
melanoma follow-up guidance in this review. All
guidelines described the lack of evidence to support
guidance on the frequency of follow-up visits. As
there is no international consensus regarding what
constitutes best practice for follow up of melanoma
survivors, the recommendations included in the
guidelines are based primarily on the relapse profile
over time. Generally, the guidelines propose that the
more advanced the stage of disease, the more fre-
quent the appointments should be and that the fre-
quency should be higher during the early follow-up
period as recurrence is more likely in patients with
advanced disease (33) and in the first years following
diagnosis (34). However, the intervals prescribed are
‘arbitrary’ and there is significant variation in the
recommendations that have been made (19). Simi-
larly, as the evidence base for the effectiveness of skin
examination and diagnostic imaging was also sparse
and of low quality, the ensuing recommendations
made by guideline developers have been largely
developed through consensus and vary as a conse-
quence.
Context of this review with other literature
These findings are very similar to those of a system-
atic review of clinical practice guidelines dealing with
prostate cancer follow up (12), which also revealed
poor methodological quality and lack of transparency
in consensus procedures, in the context of paucity of
evidence in that field of research. Another study
assessing six British cardiovascular guidelines pub-
lished by professional societies using AGREE II
found serious methodological deficiencies in all
guidelines and did not recommend any guideline for
clinical practice (13). In recent years, approaches
have been developed to increase transparency in the
development of guideline recommendations, most
noticeably the Australian FORM system, recom-
mended by the National Health and Medical
Research Council (NHMRC) (35), which mandates
the use of an evidence statement form that transpar-
ently depicts how developers move from evidence to
making a judgement and formulating a recommen-
dation. This methodological approach was used by
the CCA guideline, which received the highest scores
in our AGREE II evaluation with regards to rigour of
development. Similarly, the GRADE system – which
has been promoted heavily worldwide – provides a
more standardised approach to the development of
recommendations (36). None of the guidelines
appeared to use GRADE when formulating recom-
mendations.
Strengths and limitations
Some guidelines may have scored poorly as a result
of insufficient reporting, rather than deficient quality.
A potential weakness of this study is that guideline
authors were not contacted to confirm findings.
Hence, the scores might not be an accurate reflection
of the guideline development process. Alternatively,
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they may highlight problems in reporting by guide-
line development groups.
The AGREE II instrument has some potential
weaknesses, e.g. the items and scoring system may be
interpreted differently by appraisers, regardless of the
application of the ‘user’s manual description’, ‘how to
rate’ and ‘additional considerations’ sections provided
for each item (8). Moreover, it was suggested by one
appraiser that the addition of an item to specifically
assess the provision of tools for patients that comple-
ment clinical practice guidelines would be beneficial.
It should also be noted that AGREE II scores do
not aim to rate the quality of the recommendations
or their supporting evidence (8). For example, COG
(16) guidelines attained a relatively high ‘rigour of
development’ score, yet the evidence provided in that
guideline for melanoma follow up was limited.
Therefore, caution should be exercised as guideline
quality according to AGREE II domains reflects the
methodology of the guideline development and does
not reflect the availability of good evidence (8). Nev-
ertheless, it is evident that guidelines with low scores
in the rigour of development domain tended to pro-
vide less evidence for their recommendations.
Following the completion of our literature searches
and data analysis, NCCN released their annual
update to their guideline. Their melanoma follow-up
guidance remains unchanged. This change does not
impact on the findings of this study. The SIGN
guidelines were reaffirmed in 2011 and remain cur-
rent, although SIGN recommends the guidelines be
used with caution as they are over 7 years old.
Conclusions and implications
This review examines current international guideline
recommendations for follow up of patients with
cutaneous melanoma. The evidence base for each
guideline was evaluated and the AGREE II instru-
ment was utilised for the appraisal of guideline qual-
ity. Although most recommendations were evidence
based, the level and strength of evidence employed
was often low. Moreover, given the lack of clear
direction from the evidence base, recommendations
were often inconsistent between guidelines. All
guidelines acknowledged the lack of evidence to
some extent and the need for further research in the
field of melanoma follow up. Clinicians should rec-
ognise that further investigation into the methodol-
ogy and evidence behind the development of
recommendations are required to fully understand
the significance of melanoma follow-up recommen-
dations in the clinical setting.
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